-
2
-
-
76349110981
-
Current issues and future directions of oncolytic adenoviruses
-
Yamamoto M, Curiel DT,. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18: 243-50.
-
(2010)
Mol Ther
, vol.18
, pp. 243-250
-
-
Yamamoto, M.1
Curiel, D.T.2
-
3
-
-
33846650370
-
Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress
-
Liu TC, Galanis E, Kirn D,. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-17.
-
(2007)
Nat Clin Pract Oncol
, vol.4
, pp. 101-117
-
-
Liu, T.C.1
Galanis, E.2
Kirn, D.3
-
4
-
-
28844444483
-
Recent progress in the battle between oncolytic viruses and tumors
-
Parato KA, Senger D, Forsyth PAJ, et al. Recent progress in the battle between oncolytic viruses and tumors. Nat Rev Cancer 2005; 5: 965-76.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 965-976
-
-
Parato, K.A.1
Senger, D.2
Forsyth, P.A.J.3
-
5
-
-
76349112703
-
Intelligent design: Combination therapy with oncolytic viruses
-
Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-63.
-
(2010)
Mol Ther
, vol.18
, pp. 251-263
-
-
Ottolino-Perry, K.1
Diallo, J.S.2
Lichty, B.D.3
-
6
-
-
0032503659
-
A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
-
Freytag SO, Rogulski KR, Paielli DL, et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-33.
-
(1998)
Hum Gene Ther
, vol.9
, pp. 1323-1333
-
-
Freytag, S.O.1
Rogulski, K.R.2
Paielli, D.L.3
-
7
-
-
0033643594
-
Therapy of head and neck squamous cell carcinima with an oncolytic adenovirus expressing HSV-tk
-
Morris JC, Wildner O,. Therapy of head and neck squamous cell carcinima with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
-
(2000)
Mol Ther
, vol.1
, pp. 56-62
-
-
Morris, J.C.1
Wildner, O.2
-
8
-
-
0035893397
-
Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase
-
Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-50.
-
(2001)
Cancer Res
, vol.61
, pp. 8743-8750
-
-
Nanda, D.1
Vogels, R.2
Havenga, M.3
-
9
-
-
19944431439
-
Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: Significance of timing of 5-fluorouracil administration
-
Seo E, Abei M, Wakayama M, et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res 2005; 65: 546-52.
-
(2005)
Cancer Res
, vol.65
, pp. 546-552
-
-
Seo, E.1
Abei, M.2
Wakayama, M.3
-
10
-
-
0036837479
-
Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors
-
Oonuma M, Sunamura M, Motoi F, et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer 2002; 102: 51-9.
-
(2002)
Int J Cancer
, vol.102
, pp. 51-59
-
-
Oonuma, M.1
Sunamura, M.2
Motoi, F.3
-
11
-
-
63949083337
-
Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters
-
Bortolanza S, Bunuales M, Otano I, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17: 614-22.
-
(2009)
Mol Ther
, vol.17
, pp. 614-622
-
-
Bortolanza, S.1
Bunuales, M.2
Otano, I.3
-
12
-
-
77953160443
-
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients
-
Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-309.
-
(2010)
Cancer Res
, vol.70
, pp. 4297-4309
-
-
Cerullo, V.1
Pesonen, S.2
Diaconu, I.3
-
13
-
-
57749201655
-
Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer
-
Kirn DH, Thorne SH,. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 64-71
-
-
Kirn, D.H.1
Thorne, S.H.2
-
14
-
-
0036830143
-
Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency
-
van Beusechem VW, van den Doel PB, Grill J, et al. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002; 62: 6165-71.
-
(2002)
Cancer Res
, vol.62
, pp. 6165-6171
-
-
Van Beusechem, V.W.1
Van Den Doel, P.B.2
Grill, J.3
-
15
-
-
0041589480
-
E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer
-
Fukuda K, Abei M, Ugai H, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res 2003; 63: 4434-40.
-
(2003)
Cancer Res
, vol.63
, pp. 4434-4440
-
-
Fukuda, K.1
Abei, M.2
Ugai, H.3
-
16
-
-
34249812369
-
E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers
-
Wakayama M, Abei M, Kawashima R, et al. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin Cancer Res 2007; 13: 3043-50.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3043-3050
-
-
Wakayama, M.1
Abei, M.2
Kawashima, R.3
-
17
-
-
58349108062
-
E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer
-
Fukuda K, Abei M, Ugai H, et al. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther 2009; 16: 126-36.
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 126-136
-
-
Fukuda, K.1
Abei, M.2
Ugai, H.3
-
18
-
-
0024164649
-
Fluorouracil: Biochemistry and pharmacology
-
Pinedo HM, Peters GFJ,. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1653-1664
-
-
Pinedo, H.M.1
Peters, G.F.J.2
-
19
-
-
32944474223
-
Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors
-
Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-6.
-
(2006)
Cancer Res
, vol.66
, pp. 1270-1276
-
-
Thomas, M.A.1
Spencer, J.F.2
La Regina, M.C.3
-
20
-
-
34548473135
-
Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters
-
Bortolanza S, Alzuguren P, Bunuales M, et al. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007; 18: 681-90.
-
(2007)
Hum Gene Ther
, vol.18
, pp. 681-690
-
-
Bortolanza, S.1
Alzuguren, P.2
Bunuales, M.3
-
21
-
-
70450200778
-
The case of oncolytic viruses versus the immune system: Waiting on the judgement of Solomon
-
Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: Waiting on the judgement of Solomon. Hum Gene Ther 2009; 20: 1119-32.
-
(2009)
Hum Gene Ther
, vol.20
, pp. 1119-1132
-
-
Prestwich, R.J.1
Errington, F.2
Diaz, R.M.3
-
22
-
-
79960292554
-
Immune recruitment and therapeutic synergy: Keys to optimizing oncolytic viral therapy?
-
Naik JD, Twelves CJ, Selby PJ, et al. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res 2011; 17: 4214-24.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4214-4224
-
-
Naik, J.D.1
Twelves, C.J.2
Selby, P.J.3
-
23
-
-
85027956453
-
Thunder and lightning: Immunotherapy and oncolytic viruses collide
-
Melcher A, Parato K, Rooney CM, et al. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19: 1008-16.
-
(2011)
Mol Ther
, vol.19
, pp. 1008-1016
-
-
Melcher, A.1
Parato, K.2
Rooney, C.M.3
-
24
-
-
0034691508
-
Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
-
Chen Y, Yu DC, Charlton D, et al. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-67.
-
(2000)
Hum Gene Ther
, vol.11
, pp. 1553-1567
-
-
Chen, Y.1
Yu, D.C.2
Charlton, D.3
-
25
-
-
8444244419
-
Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model
-
Tsai V, Johnson DE, Rahman A, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004; 10: 7199-206.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7199-7206
-
-
Tsai, V.1
Johnson, D.E.2
Rahman, A.3
-
26
-
-
60049098649
-
Effect of pre-existing immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters
-
Dhar D, Spencer JF, Toth K, et al. Effect of pre-existing immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130-9.
-
(2009)
J Virol
, vol.83
, pp. 2130-2139
-
-
Dhar, D.1
Spencer, J.F.2
Toth, K.3
-
27
-
-
70349873326
-
Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model
-
Dhar D, Spencer JF, Toth K, et al. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009; 17: 1724-32.
-
(2009)
Mol Ther
, vol.17
, pp. 1724-1732
-
-
Dhar, D.1
Spencer, J.F.2
Toth, K.3
-
28
-
-
0031710507
-
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
-
Bass KK, Mastrangelo MJ,. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998; 47: 1-12.
-
(1998)
Cancer Immunol Immunother
, vol.47
, pp. 1-12
-
-
Bass, K.K.1
Mastrangelo, M.J.2
-
29
-
-
33847368549
-
+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
-
+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-8.
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 641-648
-
-
Ghiringhelli, F.1
Menard, C.2
Puig, P.E.3
-
30
-
-
80052420081
-
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
-
Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19: 1737-46.
-
(2011)
Mol Ther
, vol.19
, pp. 1737-1746
-
-
Cerullo, V.1
Diaconu, I.2
Kangasniemi, L.3
-
31
-
-
0032814773
-
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
-
Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-7.
-
(1999)
Nat Med
, vol.5
, pp. 881-887
-
-
Ikeda, K.1
Ichikawa, T.2
Wakimoto, H.3
-
32
-
-
33748088164
-
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
-
Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Accad Sci USA 2006; 103: 12873-8.
-
(2006)
Proc Natl Accad Sci USA
, vol.103
, pp. 12873-12878
-
-
Fulci, G.1
Breymann, L.2
Gianni, D.3
-
33
-
-
54749109597
-
Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model
-
Thomas MA, Spencer JF, Toth K, et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-73.
-
(2008)
Mol Ther
, vol.16
, pp. 1665-1673
-
-
Thomas, M.A.1
Spencer, J.F.2
Toth, K.3
-
34
-
-
40749090005
-
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
-
Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14: 259-69.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 259-269
-
-
Qiao, J.1
Wang, H.2
Kottke, T.3
-
35
-
-
35549009347
-
An immunocompetent murine model for oncolysis with an armed and targeted measles virus
-
Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15: 1991-7.
-
(2007)
Mol Ther
, vol.15
, pp. 1991-1997
-
-
Ungerechts, G.1
Springfeld, C.2
Frenzke, M.E.3
-
36
-
-
65249177789
-
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide
-
Lun XQ, Jang J-H, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009; 15: 2777-88.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2777-2788
-
-
Lun, X.Q.1
Jang, J.-H.2
Tang, N.3
-
37
-
-
80051580618
-
Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths
-
Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 212-236
-
-
Siegel, R.1
Ward, E.2
Brawley, O.3
-
38
-
-
0032985541
-
Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database
-
Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
-
(1999)
J Am Coll Surg
, vol.189
, pp. 1-7
-
-
Sener, S.F.1
Fremgen, A.2
Menck, H.R.3
-
39
-
-
0037279047
-
Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer
-
Dehari H, Ito Y, Nakamura T, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther 2003; 10: 75-85.
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 75-85
-
-
Dehari, H.1
Ito, Y.2
Nakamura, T.3
-
40
-
-
79959708509
-
EpCAM- and EGFR- targeted selective gene therapy for biliary cancers using Z33-fiber modified adenovirus
-
Kawashima R, Abei M, Fukuda K, et al. EpCAM- and EGFR- targeted selective gene therapy for biliary cancers using Z33-fiber modified adenovirus. Int J Cancer 2011; 129: 1244-53.
-
(2011)
Int J Cancer
, vol.129
, pp. 1244-1253
-
-
Kawashima, R.1
Abei, M.2
Fukuda, K.3
-
41
-
-
21044457510
-
Enhanced oncolysis by a tropism-modified telomerase-specific replication selective adenoviral agent OBP-405 ('Telomelysin-RGD')
-
Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005; 24: 3130-40.
-
(2005)
Oncogene
, vol.24
, pp. 3130-3140
-
-
Taki, M.1
Kagawa, S.2
Nishizaki, M.3
-
42
-
-
84874771300
-
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses
-
Peng K-W, Myers R, Greenslade A, et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 2013; 20: 255-61
-
(2013)
Gene Ther
, vol.20
, pp. 255-261
-
-
Peng, K.-W.1
Myers, R.2
Greenslade, A.3
-
44
-
-
33646907924
-
Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus
-
Zhi Y, Figueredo J, Kobinger GP, et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 2006; 17: 500-6.
-
(2006)
Hum Gene Ther
, vol.17
, pp. 500-506
-
-
Zhi, Y.1
Figueredo, J.2
Kobinger, G.P.3
-
45
-
-
0029743163
-
Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenovirus vectors to mouse liver and lung
-
Jooss K, Yang Y, Wilson JM,. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenovirus vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-66.
-
(1996)
Hum Gene Ther
, vol.7
, pp. 1555-1566
-
-
Jooss, K.1
Yang, Y.2
Wilson, J.M.3
-
46
-
-
0029934048
-
Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector
-
Smith TA, White BD, Gardner JM, et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996; 3: 496-502.
-
(1996)
Gene Ther
, vol.3
, pp. 496-502
-
-
Smith, T.A.1
White, B.D.2
Gardner, J.M.3
-
47
-
-
33751005823
-
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging
-
Lamfers M, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006; 14: 779-88.
-
(2006)
Mol Ther
, vol.14
, pp. 779-788
-
-
Lamfers, M.1
Fulci, G.2
Gianni, D.3
-
48
-
-
79960298256
-
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
-
Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011; 29: 5203-9.
-
(2011)
Vaccine
, vol.29
, pp. 5203-5209
-
-
Barouch, D.H.1
Kik, S.V.2
Weverling, G.J.3
-
49
-
-
80052406557
-
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
-
Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
-
(2011)
Nature
, vol.477
, pp. 99-102
-
-
Breitbach, C.J.1
Burke, J.2
Jonker, D.3
-
50
-
-
79953828406
-
Potential targets for pancreatic cancer immunotherapeutics
-
Dodson LF, Hawkins WG, Goedegebuure P,. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011; 3: 517-37. Technology Technology
-
(2011)
Immunotherapy
, vol.3
, pp. 517-537
-
-
Dodson, L.F.1
Hawkins, W.G.2
Goedegebuure, P.3
|